Spelling suggestions: "subject:"diabetic kidney disease"" "subject:"biabetic kidney disease""
1 |
THE CONTRIBUTIONS OF ACTIVIN B SIGNALING TO DIABETIC KIDNEY DISEASE / ACTIVIN B IN DIABETIC KIDNEY DISEASEKhajehei, Mohammad January 2022 (has links)
DKD is the leading cause of kidney failure in Canada and its patients suffer the highest morbidity and mortality rates of any kidney failure patient group. Current interventions including strict glycemic control only delay DKD. Thus, there is a major need to identify new therapeutic targets. High glucose (HG) is identified as a major pathogenic factor, inducing the release of growth factors leading to kidney fibrosis. Although treatments have been developed to target these factors, their effectiveness is accompanied by adverse effects due to the lack of specificity. Recently, activins have been suggested to have a prominent role in promoting renal fibrosis and developing a specific anti-activin therapy can avoid potential side effects. Although there is evidence supporting an important role for activin A (ActA) in the induction of fibrosis in DKD, whether ActB also contributes is unknown. In this study, we aim to determine the potential contribution of ActB to promoting fibrosis. Our results show that ActA and ActB are upregulated in rodent and human DKD. We show that hyperglycemia leads to the secretion of ActA and ActB by mesangial cells (MC), whereas only ActB is secreted by renal fibroblasts (RF). Similar to HG, treatment with ActA or ActB leads to Smad2/3 activation and upregulation of extracellular matrix proteins, whereas specific inhibition of either ActA or ActB attenuates these effects. We show that ActA and ActB regulate HG-induced activation of MRTF-A/SRF in MC, leading to an activated phenotype characterized by increased α-SMA expression and ECM production. Lastly, we confirm the specificity and functionality of the activin propeptides in vitro, providing evidence for their effectiveness in vivo. This study will help further our knowledge of the role activins in DKD, potentially providing an alternative therapy. / Thesis / Master of Science (MSc) / As the leading cause of end stage renal disease, diabetic kidney disease (DKD) is described as the reduction in renal function due to chronic exposure to diabetes. This thesis is aimed to understand the pathways and mechanisms that contribute to the development and progression of DKD to help identify novel therapeutic options. This project identified activin B (ActB) as a contributor to the disease and gives evidence that blocking the actions of ActB can prevent profibrotic effects in cells, similar to the profibrotic effects seen in DKD. Furthermore, this thesis demonstrates preliminary evidence for the beneficial effects of anti-ActB therapy, providing a potential alternative therapeutic option for DKD patients.
|
2 |
The Role of Thromboxane A2 Receptors in Diabetic Kidney DiseaseShaji, Roya 08 February 2011 (has links)
Thromboxane receptor (TPr) activity is elevated in diabetes and contributes to
complications of diabetic kidney disease (DKD). TPr blockade appears to have
therapeutic potential. Several rodent models of DKD show attenuation of renal damage
and proteinuria upon administration of the TPr antagonist, S18886. However, the
cellular targets that underlie the injurious effects of TPr activation in DKD remain to be
elucidated.
A pilot study in our laboratory subjected a conditionally-immortalized mouse
podocyte cell line to high glucose (25 mM D-glucose) and equibiaxial mechanical
stretch (an in vitro simulator of increased glomerular capillary pressure associated with
glomerular hyperfiltration in early diabetes). qRT-PCR revealed that exposure of
podocytes to mechanical stretch (10% elongation) and high glucose for 6 hours yielded
a 9-fold increase in TPr mRNA levels vs. controls (non-stretch, 5mM D-glucose + 25mM
L-glucose) (p<0.05, n=5). We hypothesized that TPr expression and activity are
increased in podocytes during the onset of DKD resulting in maladaptive effects on this
key glomerular filtration barrier cell type.
We showed that enhanced TPr signaling threatens podocytes viablility. Cultured
podocytes treated with the TPr agonist, U-46619 (1 μM) for 24 hours are more
vulnerable to apoptosis as quantified by Hoescht 33342 (20% cell death p<0.001, n=3) ,
TUNEL (30-fold increase, ns, n=3) and Annexin-V labeling (3-fold increase, p <0.001,
n=3). To further support these in vitro findings, we developed a transgenic mouse with
podocyte-specific overexpression of TPr. A construct consisting of a desensitization
resistant mutant of the human TPr with both N- and C-terminal HA-epitope tags under the control of an 8.3 kb fragment of the immediate 5’ mouse NPHS1 promoter was cloned, isolated and injected into FVB/n oocytes that were implanted into
pseudopregnant CD1 females. Founders were characterized for TPr transgene expression, and TPr transgene mRNA levels were detected by qRT-PCR.
Our in vitro results suggest that increased TPr expression in podocytes of
diabetic mice may contribute to filtration barrier damage and have important implications
in the development and progression of DKD.
|
3 |
The Role of Thromboxane A2 Receptors in Diabetic Kidney DiseaseShaji, Roya 08 February 2011 (has links)
Thromboxane receptor (TPr) activity is elevated in diabetes and contributes to
complications of diabetic kidney disease (DKD). TPr blockade appears to have
therapeutic potential. Several rodent models of DKD show attenuation of renal damage
and proteinuria upon administration of the TPr antagonist, S18886. However, the
cellular targets that underlie the injurious effects of TPr activation in DKD remain to be
elucidated.
A pilot study in our laboratory subjected a conditionally-immortalized mouse
podocyte cell line to high glucose (25 mM D-glucose) and equibiaxial mechanical
stretch (an in vitro simulator of increased glomerular capillary pressure associated with
glomerular hyperfiltration in early diabetes). qRT-PCR revealed that exposure of
podocytes to mechanical stretch (10% elongation) and high glucose for 6 hours yielded
a 9-fold increase in TPr mRNA levels vs. controls (non-stretch, 5mM D-glucose + 25mM
L-glucose) (p<0.05, n=5). We hypothesized that TPr expression and activity are
increased in podocytes during the onset of DKD resulting in maladaptive effects on this
key glomerular filtration barrier cell type.
We showed that enhanced TPr signaling threatens podocytes viablility. Cultured
podocytes treated with the TPr agonist, U-46619 (1 μM) for 24 hours are more
vulnerable to apoptosis as quantified by Hoescht 33342 (20% cell death p<0.001, n=3) ,
TUNEL (30-fold increase, ns, n=3) and Annexin-V labeling (3-fold increase, p <0.001,
n=3). To further support these in vitro findings, we developed a transgenic mouse with
podocyte-specific overexpression of TPr. A construct consisting of a desensitization
resistant mutant of the human TPr with both N- and C-terminal HA-epitope tags under the control of an 8.3 kb fragment of the immediate 5’ mouse NPHS1 promoter was cloned, isolated and injected into FVB/n oocytes that were implanted into
pseudopregnant CD1 females. Founders were characterized for TPr transgene expression, and TPr transgene mRNA levels were detected by qRT-PCR.
Our in vitro results suggest that increased TPr expression in podocytes of
diabetic mice may contribute to filtration barrier damage and have important implications
in the development and progression of DKD.
|
4 |
The Role of Thromboxane A2 Receptors in Diabetic Kidney DiseaseShaji, Roya 08 February 2011 (has links)
Thromboxane receptor (TPr) activity is elevated in diabetes and contributes to
complications of diabetic kidney disease (DKD). TPr blockade appears to have
therapeutic potential. Several rodent models of DKD show attenuation of renal damage
and proteinuria upon administration of the TPr antagonist, S18886. However, the
cellular targets that underlie the injurious effects of TPr activation in DKD remain to be
elucidated.
A pilot study in our laboratory subjected a conditionally-immortalized mouse
podocyte cell line to high glucose (25 mM D-glucose) and equibiaxial mechanical
stretch (an in vitro simulator of increased glomerular capillary pressure associated with
glomerular hyperfiltration in early diabetes). qRT-PCR revealed that exposure of
podocytes to mechanical stretch (10% elongation) and high glucose for 6 hours yielded
a 9-fold increase in TPr mRNA levels vs. controls (non-stretch, 5mM D-glucose + 25mM
L-glucose) (p<0.05, n=5). We hypothesized that TPr expression and activity are
increased in podocytes during the onset of DKD resulting in maladaptive effects on this
key glomerular filtration barrier cell type.
We showed that enhanced TPr signaling threatens podocytes viablility. Cultured
podocytes treated with the TPr agonist, U-46619 (1 μM) for 24 hours are more
vulnerable to apoptosis as quantified by Hoescht 33342 (20% cell death p<0.001, n=3) ,
TUNEL (30-fold increase, ns, n=3) and Annexin-V labeling (3-fold increase, p <0.001,
n=3). To further support these in vitro findings, we developed a transgenic mouse with
podocyte-specific overexpression of TPr. A construct consisting of a desensitization
resistant mutant of the human TPr with both N- and C-terminal HA-epitope tags under the control of an 8.3 kb fragment of the immediate 5’ mouse NPHS1 promoter was cloned, isolated and injected into FVB/n oocytes that were implanted into
pseudopregnant CD1 females. Founders were characterized for TPr transgene expression, and TPr transgene mRNA levels were detected by qRT-PCR.
Our in vitro results suggest that increased TPr expression in podocytes of
diabetic mice may contribute to filtration barrier damage and have important implications
in the development and progression of DKD.
|
5 |
The Role of Thromboxane A2 Receptors in Diabetic Kidney DiseaseShaji, Roya January 2011 (has links)
Thromboxane receptor (TPr) activity is elevated in diabetes and contributes to
complications of diabetic kidney disease (DKD). TPr blockade appears to have
therapeutic potential. Several rodent models of DKD show attenuation of renal damage
and proteinuria upon administration of the TPr antagonist, S18886. However, the
cellular targets that underlie the injurious effects of TPr activation in DKD remain to be
elucidated.
A pilot study in our laboratory subjected a conditionally-immortalized mouse
podocyte cell line to high glucose (25 mM D-glucose) and equibiaxial mechanical
stretch (an in vitro simulator of increased glomerular capillary pressure associated with
glomerular hyperfiltration in early diabetes). qRT-PCR revealed that exposure of
podocytes to mechanical stretch (10% elongation) and high glucose for 6 hours yielded
a 9-fold increase in TPr mRNA levels vs. controls (non-stretch, 5mM D-glucose + 25mM
L-glucose) (p<0.05, n=5). We hypothesized that TPr expression and activity are
increased in podocytes during the onset of DKD resulting in maladaptive effects on this
key glomerular filtration barrier cell type.
We showed that enhanced TPr signaling threatens podocytes viablility. Cultured
podocytes treated with the TPr agonist, U-46619 (1 μM) for 24 hours are more
vulnerable to apoptosis as quantified by Hoescht 33342 (20% cell death p<0.001, n=3) ,
TUNEL (30-fold increase, ns, n=3) and Annexin-V labeling (3-fold increase, p <0.001,
n=3). To further support these in vitro findings, we developed a transgenic mouse with
podocyte-specific overexpression of TPr. A construct consisting of a desensitization
resistant mutant of the human TPr with both N- and C-terminal HA-epitope tags under the control of an 8.3 kb fragment of the immediate 5’ mouse NPHS1 promoter was cloned, isolated and injected into FVB/n oocytes that were implanted into
pseudopregnant CD1 females. Founders were characterized for TPr transgene expression, and TPr transgene mRNA levels were detected by qRT-PCR.
Our in vitro results suggest that increased TPr expression in podocytes of
diabetic mice may contribute to filtration barrier damage and have important implications
in the development and progression of DKD.
|
6 |
Network Analysis Reveals Aberrant Cell Signaling in Murine Diabetic KidneyGopal, Priyanka 03 June 2015 (has links)
No description available.
|
7 |
CELL SURFACE GRP78 PARTICIPATES IN THE UPREGULATION OF TGFβ1 SIGNALING BY HIGH GLUCOSEZheng, Mengyu January 2018 (has links)
Diabetic nephropathy (DN) affects around 40% of diabetic patients worldwide and has become a major health concern due to its high morbidity and mortality. The progression of DN is characterized by the thickening of glomerular basement membrane, albuminuria and the development of glomerulosclerosis. Renal function is eventually compromised. Due to various hemodynamic and metabolic changes, especially the elevated blood glucose level in diabetic patients, glomerular mesangial cells have been shown to upregulate transforming growth factor-β1 (TGF-β1) level and signaling, resulting in the excessive production of extracellular matrix (ECM) proteins. The atypical expression of the 78-kDa glucose-regulated protein (GRP78) on the cell surface may be associated with this pro-fibrotic effect through its interaction with the TGF-β1 activation process. However, there is no current literature demonstrating the role of cell surface GRP78 (csGRP78) in the pathogenesis of diabetic renal diseases. The purpose of my MSc project was to determine the role of csGRP78 in TGF-β1 synthesis and activation and thereby in the progression of DN. We hypothesized that the increased expression of csGRP78 in response to high glucose exposure stimulates TGF-β1 upregulation through intracellular signaling, as well as its activation through interaction with the latent complex, which leads to the expansion of mesangial matrix. / Thesis / Master of Science (MSc) / Diabetic kidney disease affects around 40% of diabetic patients worldwide and is a major health concern. A major feature of the disease is glomerulosclerosis, which is the scarring of glomeruli. The glomeruli filter blood passing through blood vessels in the kidneys to remove waste, which will then be excreted into urine. In diabetic patients, high blood glucose causes the fibrosis of glomeruli and damages the filtration barrier. As a result, a large amount of proteins leak from the blood into the urine. It has been discovered that TGF-β1 is one of the key molecules mediating the generation of scar tissue in the glomerulus. It promotes the growth of mesangial cells, a major type of kidney glomerular cells, and stimulates their production of extracellular matrix proteins. Our results showed that GRP78, a protein that is primarily expressed in the endoplasmic reticulum and assists with protein folding, moves from the inside of cells to the surface in response to a high glucose environment. Here, we found that it facilitated TGF-β1 signaling. Based on our studies, we propose that when GRP78 is at the cell surface, it enables the release of latent TGF-β1, increasing TGF-β1 activity and thus promoting the development of disease.
|
8 |
Inhibition of inflammatory cytokines - potential new treatment for diabetic nephropathyCorreia, Amanda 08 April 2016 (has links)
Type II diabetes mellitus is currently on the rise and reaching epidemic proportions in the United States. In addition to this increase, the number of cases of diabetic complication such as kidney disease has increased. Currently diabetic kidney disease is the leading cause for end stage renal disease in the United States accounting for nearly half of all cases. Type II diabetes is the result of metabolic, hemodynamic and inflammatory alterations within the body. Currently there is a standard of care to treat both metabolic and hemodynamic perturbations by enforcing tight glycemic control and utilizing anti-hypertensive drugs, most notably RAS inhibitors. These therapeutic interventions however, are not sufficient as many patients with type II diabetes will still develop diabetic kidney disease therefore another treatment option is imperative. Currently there are no treatments available to counteract the adverse inflammatory responses associated with type II diabetes which are strong contributors to the progression of the diabetic kidney disease. Among the inflammatory parameters studied as potential targets for therapeutic intervention the inflammatory cytokine tumor necrosis factor-α (TNF-α) stands out among the rest for its multifaceted role in disease progression.
TNF-α has been shown to both directly and indirectly involved in development and progression of diabetic kidney disease. The inflammatory cytokine itself is toxic to renal cells initially increasing the permeability of the glomerular filtration barrier and contributing to proteinuria which eventually causes cellular apoptosis. TNF-α also activates second messengers and up-regulates transcription factors that further contribute to the progression of diabetic kidney disease.
Two TNF-α inhibitors, pentoxifylline and chrysin have stood out among the other investigational drugs which have been studied as potential therapeutic options to delay the progression of diabetic kidney disease. Pentoxifylline is a methyl-xanthine derivative that is currently used to treat peripheral vascular disease. It has shown good effect in clinical trials decreasing both urinary TNF-α concentrations as well as urinary protein excretion. Chrysin is a natural plant derivative belonging to the flavonoid family and is known for its anti-inflammatory and anti-oxidant properties. Currently chrysin has only been studied in animal models of diabetic kidney disease but has shown to not only decrease concentrations of inflammatory cytokines to control levels and improve renal functions but also prevented the histopathological changes associated with diabetic kidney disease suggesting that chrysin has the ability to not only slow the progression of disease and preserve renal function, it has the ability to prevent the disease from ever taking root.
Diabetic kidney disease is a devastating disease affecting millions of people worldwide. It is important for further investigation with these investigational drugs to be performed in large scale clinical trials to produce safety and efficacy data with the end goal of becoming approved as new treatments for diabetic kidney disease.
|
9 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess / サクビトリル/バルサルタンのアルドステロン過剰を伴う2型糖尿病モデルマウスにおける腎血漿流量増加を介した腎尿細管間質障害改善効果に関する研究Nishio, Haruomi 23 January 2024 (has links)
京都大学 / 新制・課程博士 / 博士(医学) / 甲第24999号 / 医博第5033号 / 新制||医||1070(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 長船 健二, 教授 小林 恭, 教授 尾野 亘 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
10 |
Increased Urinary Angiotensin Converting Enzyme 2 (ACE2) and Neprilysin (NEP) in Type 2 Diabetic PatientsGutta, Sridevi January 2014 (has links)
No description available.
|
Page generated in 0.0641 seconds